Trial Profile
A Clinic-Based, Phase IIa, Double-Blind, Placebo- Controlled, Ascending-Dose, Multicentre Study of Safety, Tolerability, Efficacy and Pharmacokinetics of VR040 in Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2016
Price :
$35
*
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 01 Sep 2013 Primary endpoint 'Unified-Parkinson's-Disease-Rating-Scale' has been met.
- 28 Sep 2012 New trial record